乳房外Paget病的治疗进展

doi:10.3760/cma.j.cn371439-20230322-00071

摘要/Abstract

摘要：

乳房外Paget病是一种临床上较为少见的皮肤恶性肿瘤，外科手术治疗为其主要治疗手段，莫氏显微外科手术是其首选治疗方案，可精确控制手术切缘并降低复发率。由于乳房外Paget病的隐匿性和多灶性，术后复发率仍较高。其他的治疗手段包括放疗、化疗、靶向治疗、光动力治疗、局部药物治疗以及激光治疗等。进一步研究乳房外Paget病治疗进展将为临床此类患者的管理及治疗提供新的思路。

关键词: 治疗, 乳房外Paget病

Abstract:

Extramammary Paget disease （EMPD） is a kind of rare clinical malignant tumor in the skin. Surgical treatment is the main treatment method，and the Mohs microsurgery is considered the first choice which can control the incision margin accurately and reduce the recurrence rate. Due to the insidious and multifocal nature of the disease，the postoperative recurrence rate is still high. The other treatment methods include radiation therapy，chemotherapy，targeted therapy，photodynamic therapy，local drug therapy and laser therapy. Further research on the progress of EMPD treatment is helpful for the management and treatment of patients in clinical practice.

Key words: Therapy, Extramammary Paget disease

成娟, 陈宏. 乳房外Paget病的治疗进展[J]. 国际肿瘤学杂志, 2023, 50(6): 357-361.

Cheng Juan, Chen Hong. Advances in the treatment of extramammary Paget disease[J]. Journal of International Oncology, 2023, 50(6): 357-361.

参考文献 47

[1]	Yamaguchi A, Takahashi T, Kato T, et al. Immunohistochemical and clinicopathological study regarding nardilysin on extramammary Paget's disease[J/OL]. Arch Dermatol Res. [2023-03-03]. https://pubmed.ncbi.nlm.nih.gov/36867223/. DOI: 10.1007/s00403-023-02579-5. doi: 10.1007/s00403-023-02579-5
[2]	Dai C, Baird BA, Lyon TD, et al. Extramammary paget disease of the axilla and scrotum in a Caucasian man[J]. JAAD Case Rep, 2022, 23: 87-89. DOI: 10.1016/j.jdcr.2022.03.004. doi: 10.1016/j.jdcr.2022.03.004 pmid: 35465136
[3]	Zhao C, Zhang G, Li Y, et al. Concurrent extramammary Paget's disease involving the genitalia and axilla: case report and literature review[J]. Australas J Dermatol, 2022, 63(3): e226-e230. DOI: 10.1111/ajd.13883. doi: 10.1111/ajd.13883
[4]	Chung PH, Leong JY, Voelzke BB. Surgical experience with genital and perineal extramammary Paget's disease[J]. Urology, 2019, 128: 90-95. DOI: 10.1016/j.urology.2019.03.006. doi: S0090-4295(19)30249-3 pmid: 30902697
[5]	Kaku-Ito Y, Ito T, Tsuji G, et al. Evaluation of mapping biopsies for extramammary Paget disease: a retrospective study[J]. J Am Acad Dermatol, 2018, 78(6): 1171-1177. e4. DOI: 10.1016/j.jaad.2017.12.040. doi: S0190-9622(17)32880-3 pmid: 29277730
[6]	Maeda T, Nagai K, Uehara J, et al. Sentinel lymph node biopsy in extramammary Paget disease: a 13-year institutional experience[J]. J Dermatol, 2023, 50(1): 57-63. DOI: 10.1111/1346-8138.16602. doi: 10.1111/1346-8138.16602
[7]	Hashimoto H, Ito T. Current management and treatment of extramammary Paget's disease[J]. Curr Treat Options Oncol, 2022, 23(6): 818-830. DOI: 10.1007/s11864-021-00923-3. doi: 10.1007/s11864-021-00923-3
[8]	Brough K, Carley SK, Vidal NY. The treatment of anogenital extramammary Paget's disease as part of a multidisciplinary approach: the use of Mohs surgery moat method with CK7[J]. Int J Dermatol, 2022, 61(2): 238-245. DOI: 10.1111/ijd.15847. doi: 10.1111/ijd.15847
[9]	Kim SJ, Thompson AK, Zubair AS, et al. Surgical treatment and outcomes of patients with extramammary Paget disease: a cohort study[J]. Dermatol Surg, 2017, 43(5): 708-714. DOI: 10.1097/DSS.0000000000001051. doi: 10.1097/DSS.0000000000001051 pmid: 28178005
[10]	Bittar JM, Bittar PG, Nugent ST, et al. Interdisciplinary management of extramammary Paget's disease using Mohs micrographic surgery with frozen section cytokeratin-7 immunostains[J]. Urology, 2022, 166: 164-169. DOI: 10.1016/j.urology.2022.04.036. doi: 10.1016/j.urology.2022.04.036
[11]	Damavandy AA, Terushkin V, Zitelli JA, et al. Intraoperative immunostaining for cytokeratin-7 during Mohs micrographic surgery demonstrates low local recurrence rates in extramammary Paget's disease[J]. Dermatol Surg, 2018, 44(3): 354-364. DOI: 10.1097/DSS.0000000000001355. doi: 10.1097/DSS.0000000000001355 pmid: 29517496
[12]	Li Q, Zhang G, Yao X, et al. Prediction of surgical margin width using Mohs micrographic surgery for extramammary Paget's disease based on clinicopathological parameters: classification tree analysis of 150 cases[J]. Eur J Dermatol, 2022, 32(1): 107-112. DOI: 10.1684/ejd.2022.4204. doi: 10.1684/ejd.2022.4204
[13]	Song C, Li JH, Luo XY, et al. The clinical effect of modified slow Mohs circular skin biopsy on penoscrotal extramammary Paget's disease[J/OL]. Asian J Surg. [2023-02-01]. https://pubmed.ncbi.nlm.nih.gov/36737341/. DOI: 10.1016/j.asjsur.2023.01.079. doi: 10.1016/j.asjsur.2023.01.079
[14]	Asilian A, Honarjou N, Faghihi G, et al. An experience of slow-Mohs micrographic surgery for the treatment of Dermatofibrosarcoma protuberans: a long-term cohort study[J]. J Cosmet Dermatol, 2020, 19(10): 2701-2705. DOI: 10.1111/jocd.13319. doi: 10.1111/jocd.13319
[15]	Litaiem N, Karray M, Jones M, et al. Effectiveness of dermoscopy in the demarcation of surgical margins in slow Mohs surgery[J]. Dermatol Ther, 2020, 33(6): e14196. DOI: 10.1111/dth.14196. doi: 10.1111/dth.14196
[16]	Seo J, Oh Y, Kim SK, et al. Slow Mohs micrographic surgery for acral melanoma treatment in Korean patients[J]. Dermatol Surg, 2021, 47(2): e42-e46. DOI: 10.1097/DSS.0000000000002827. doi: 10.1097/DSS.0000000000002827 pmid: 33481431
[17]	Snast I, Sharon E, Kaftory R, et al. Nonsurgical treatments for extramammary Paget disease: a systematic review and meta-analysis[J]. Dermatology, 2020, 236(6): 493-499. DOI: 10.1159/000506832. doi: 10.1159/000506832
[18]	Suzuki G, Machida K, Asato A, et al. Definitive radiotherapy for penoscrotal extramammary Paget's disease: a case report with long-term follow-up[J]. Clin Med Insights Case Rep, 2021, 14: 11795 476211009251. DOI: 10.1177/11795476211009251. doi: 10.1177/11795476211009251
[19]	Piras A, Sanfratello A, Boldrini L, et al. Paget's disease of scrotum and penis case report of a re-irradiation and review of the literature[J]. Dermatol Ther, 2020, 33(6): e13890. DOI: 10.1111/dth.13890. doi: 10.1111/dth.13890
[20]	Okumura M, Ogata D, Namikawa K, et al. Postoperative radiation therapy improves prognoses in extramammary Paget's disease presenting with multiple lymph node metastases[J]. J Dermatol, 2022, 49(10): 1005-1011. DOI: 10.1111/1346-8138.16491. doi: 10.1111/1346-8138.16491
[21]	Tsutsui K, Takahashi A, Muto Y, et al. Outcomes of lymph node dissection in the treatment of extramammary Paget's disease: a single-institution study[J]. J Dermatol, 2020, 47(5): 512-517. DOI: 10.1111/1346-8138.15285. doi: 10.1111/1346-8138.15285
[22]	Chen K, Liang H, Peng J, et al. Successful treatment of metastatic extramammary Paget's disease with pemetrexed monotherapy systemically and 5-fluorouracil topically[J]. Indian J Dermatol Venereol Leprol, 2019, 85(1): 56-59. DOI: 10.4103/ijdvl.IJDVL_171_17. doi: 10.4103/ijdvl.IJDVL_171_17 pmid: 29536970
[23]	Aroche Gutierrez SBLL, Holloway SB, Donthi D, et al. Docetaxel treatment for widely metastatic invasive vulvar extramammary Paget's disease with multifocal bone metastasis[J]. Gynecol Oncol Rep, 2023, 45: 101114. DOI: 10.1016/j.gore.2022.101114. doi: 10.1016/j.gore.2022.101114
[24]	Maeda T, Kitamura S, Nishihara H, et al. Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies[J]. Oncogene, 2020, 39(36): 5867-5875. DOI: 10.1038/s41388-020-01404-x. doi: 10.1038/s41388-020-01404-x pmid: 32724160
[25]	Nakamura Y, Tanese K, Hirai I, et al. Weekly docetaxel monotherapy for metastatic extramammary Paget's disease: retrospective single-institute analysis[J]. J Dermatol, 2020, 47(4): 418-422. DOI: 10.1111/1346-8138.15255. doi: 10.1111/1346-8138.15255
[26]	Angelico G, Santoro A, Inzani F, et al. Hormonal environment and HER2 status in extra-mammary Paget's disease (eMPD): a syste-matic literature review and meta-analysis with clinical conside-rations[J]. Diagnostics (Basel), 2020, 10(12): 1040. DOI: 10.3390/diagnostics10121040. doi: 10.3390/diagnostics10121040
[27]	Lu X, Zhang P, Zhu Y, et al. Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease[J]. Oncol Lett, 2019, 17(3): 2677-2686. DOI: 10.3892/ol.2019.9930. doi: 10.3892/ol.2019.9930 pmid: 30854041
[28]	Tokuchi K, Maeda T, Kitamura S, et al. HER2-targeted antibody-drug conjugates display potent antitumor activities in preclinical extramammary Paget's disease models: in vivo and immunohistochemical analyses[J]. Cancers (Basel), 2022, 14(14): 3519. DOI: 10.3390/cancers14143519. doi: 10.3390/cancers14143519
[29]	Sola-Ortigosa J, Muñoz-Santos C, Hernández-Bronchud M, et al. Cutaneous apocrine adenocarcinoma of the groin with extramammary Paget disease: response to dual HER2 blockade with trastuzumab and pertuzumab[J]. Actas Dermosifiliogr, 2022, 113(10): 973-975. DOI: 10.1016/j.ad.2021.04.010. doi: 10.1016/j.ad.2021.04.010
[30]	Zattarin E, Nichetti F, Ligorio F, et al. Case report: prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin[J]. Front Oncol, 2022, 12: 925551. DOI: 10.3389/fonc.2022.925551. doi: 10.3389/fonc.2022.925551
[31]	Kitamura S, Yanagi T, Maeda T, et al. Cyclin-dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget's disease[J]. Cancer Sci, 2022, 113(2): 802-807. DOI: 10.1111/cas.15234. doi: 10.1111/cas.15234
[32]	Hashimoto H, Kaku-Ito Y, Oda Y, et al. CDK4: a novel therapeutic target for extramammary Paget's disease[J]. Front Oncol, 2021, 11: 710378. DOI: 10.3389/fonc.2021.710378. doi: 10.3389/fonc.2021.710378
[33]	Li X, Zhao C, Kou H, et al. PDD-guided tumor excision combined with photodynamic therapy in patients with extramammary Paget's disease[J]. Photodiagnosis Photodyn Ther, 2022, 38: 102841. DOI: 10.1016/j.pdpdt.2022.102841. doi: 10.1016/j.pdpdt.2022.102841
[34]	Zhou P, Li J, Song C, et al. The application of Wood's lamp combined with 5-aminolevulinic acid for defining tumor margins in patients with extramammary Paget's disease[J]. Photodiagnosis Photodyn Ther, 2021, 35: 102490. DOI: 10.1016/j.pdpdt.2021.102490. doi: 10.1016/j.pdpdt.2021.102490
[35]	Gunaydin G, Gedik ME, Ayan S. Photodynamic therapy-current limitations and novel approaches[J]. Front Chem, 2021, 9: 691697. DOI: 10.3389/fchem.2021.691697. doi: 10.3389/fchem.2021.691697
[36]	Cramer GM, Cengel KA, Busch TM. Forging forward in photodynamic therapy[J]. Cancer Res, 2022, 82(4): 534-536. DOI: 10.1158/0008-5472.CAN-21-4122. doi: 10.1158/0008-5472.CAN-21-4122 pmid: 35180305
[37]	Shim PJ, Zeitouni NC. Photodynamic therapy for extramammary Paget's disease: a systematic review of the literature[J]. Photodiagnosis Photodyn Ther, 2020, 31: 101911. DOI: 10.1016/j.pdpdt.2020.101911. doi: 10.1016/j.pdpdt.2020.101911
[38]	Wang D, Wang P, Li C, et al. Efficacy and safety of HpD-PDT for extramammary Paget's disease refractory to conventional therapy: a prospective, open-label and single arm pilot study[J]. Photodiagnosis Photodyn Ther, 2022, 37: 102670. DOI: 10.1016/j.pdpdt.2021.102670. doi: 10.1016/j.pdpdt.2021.102670
[39]	Christodoulidou M, Alnajjar HM, Parnham A, et al. Multidisciplinary approach for the management of penoscrotal extramammary Paget's disease—an eUROGEN study[J]. Urol Oncol, 2021, 39(8): 501. e1-501.e10. DOI: 10.1016/j.urolonc.2021.05.018. doi: 10.1016/j.urolonc.2021.05.018
[40]	Lin JD, Li MH, Wu TH, et al. Combined methyl aminolevulinate-based photodynamic therapy and imiquimod in a patient with perianal extramammary Paget's disease[J]. Photodiagnosis Photodyn Ther, 2021, 35: 102407. DOI: 10.1016/j.pdpdt.2021.102407. doi: 10.1016/j.pdpdt.2021.102407
[41]	van der Linden M, van Hees CL, van Beurden M, et al. The Paget trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease[J]. Am J Obstet Gynecol, 2022, 227(2): 250.e1-250.e8. DOI: 10.1016/j.ajog.2022.04.012. doi: 10.1016/j.ajog.2022.04.012
[42]	Sawada M, Kato J, Yamashita T, et al. Imiquimod 5% cream as a therapeutic option for extramammary Paget's disease[J]. J Dermatol, 2018, 45(2): 216-219. DOI: 10.1111/1346-8138.14117. doi: 10.1111/1346-8138.14117
[43]	Borella F, Preti M, Vieira-Baptista P, et al. Vulvar Paget's disease: outcomes of 51 patients treated with imiquimod cream[J]. Maturitas, 2022, 163: 23-27. DOI: 10.1016/j.maturitas.2022.05.010. doi: 10.1016/j.maturitas.2022.05.010 pmid: 35661559
[44]	Choi S, Oh Y, Roh MR, et al. Initial topical monotherapy may increase the risk of recurrence in patients with extramammary Paget's disease[J]. J Dermatol, 2021, 48(5): 585-591. DOI: 10.1111/1346-8138.15794. doi: 10.1111/1346-8138.15794
[45]	Molina GE, Khalifian S, Mull JL, et al. Topical combination of fluorouracil and calcipotriene as a palliative therapy for refractory extramammary Paget disease[J]. JAMA Dermatol, 2019, 155(5): 599-603. DOI: 10.1001/jamadermatol.2018.4793. doi: 10.1001/jamadermatol.2018.4793 pmid: 30785593
[46]	Li C, Guo L, Wang P, et al. ALA-PDT combined with holmium laser therapy of postoperative recurrent extramammary Paget's disease[J]. Photodiagnosis Photodyn Ther, 2019, 27: 92-94. DOI: 10.1016/j.pdpdt.2019.05.011. doi: S1572-1000(19)30190-5 pmid: 31100448
[47]	Ferrara F, Bardazzi F, Messori S, et al. Photodynamic therapy following fractional CO₂ laser for treatment of primary vulvar Paget's disease: does it really work?[J]. J Dermatolog Treat, 2021, 32(7): 800-802. DOI: 10.1080/09546634.2019.1707755. doi: 10.1080/09546634.2019.1707755